- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02815774
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients
23. juni 2016 opdateret af: Jiangsu HengRui Medicine Co., Ltd.
A Parallel, Open Phase Ih Study to Access the Pharmacokinetic of SP2086 in Renal Insufficiency Patients
The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.
Studieoversigt
Detaljeret beskrivelse
This trial adopt in a parallel, open, single dose study design.
The subject was divided into one of five groups according to the degree of renal Insufficiency, which including normal, mild, moderate, severe, and end-stage.
All subjects were given SP2086 50mg, and collected the blood samples before and after the medicine taken.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
30
Fase
- Fase 1
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 79 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- with a body mass index(BMI) between 19 and 28 Kg/m2;Weight:≥50Kg(male),≥45kg(female)
- The endogenous creatinine clearance of subjects in groups must meet the standards of Ccr in renal function in installment:mild renal insufficiency:60-89 - ml/min;Moderate renal insufficiency: 30 to 59 ml/min;Severe renal insufficiency: 15-29 ml/min;End-stage renal disease: < 15 ml/min.Normal renal function: 90 ml/min or more.
- Had signed the informed consent himself or herself voluntarily.
Exclusion Criteria:
- Cannot tolerate oral medicine.
- Not control or unstable cardiovascular, respiratory, liver, digestive, endocrine, hematopoietic, the mental or nerve system diseases.
- Had the digestive surgery that could affect drug absorption.
- The clinical significance of arrhythmia.
- Acute hepatitis, chronic liver disease; ALT or AST value was 2 times greater than upper normal limit, Total bilirubin value was 1.5 times greater than upper normal limit.
- HBV surface antigen, HCV antibody, or HIV antibody was positive.
- history of drug allergy or allergic constitution or family history of allergy.
- Had Used hormonal contraception within 3 months;
- Had Used DPP - IV inhibitor within 2 weeks;
- Had Used traditional Chinese medicine (Chinese herbs, Chinese patent medicine) within 2 weeks;
- Had Used acid inhibitors within 2 weeks;
- Alcohol, tobacco, drug abusers;alcohol abuse is defined as a day for regular alcohol consumption more than the following standards: beer 570 ml, light beer 750 ml, red wine 200 ml, white wine 60 ml, which including about 20g alcohol;Tobacco is defined as five or more per day.
- 2 days before the randomization till to the end ,the patients can not ban alcohol, tobacco, or reference food or drink containing caffeine or xanthine , or vigorous exercise, or there are other factors that can affect drug absorption, distribution, metabolism and excretion
- The patient had participated three times or more clinical trial in one year, or one time within 3 months.
- Pregnancy or lactation women, or a fertility male or female is not willing to contraception during test.
- History of blood donation or participate in blood donation, or by blood transfusion in 3 months prior to screening.
- Researchers considered that there was any situation that may cause the participants can't finish this study or bring any obvious risk to subjects.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: health volunteers
this group patients were given SP2086 50mg only one time.
|
all subjects were given SP2086 50mg only one time.
|
|
Aktiv komparator: mild renal insufficiency
this group patients were given SP2086 50mg only one time.
|
all subjects were given SP2086 50mg only one time.
|
|
Aktiv komparator: moderate renal insufficiency
this group patients were given SP2086 50mg only one time.
|
all subjects were given SP2086 50mg only one time.
|
|
Aktiv komparator: severe renal insufficiency
this group patients were given SP2086 50mg only one time.
|
all subjects were given SP2086 50mg only one time.
|
|
Aktiv komparator: end-stage renal insufficiency
this group patients were given SP2086 50mg only one time.
|
all subjects were given SP2086 50mg only one time.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The maximum plasma concentration (Cmax) of SP2086
Tidsramme: up to 96 hours
|
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
|
up to 96 hours
|
|
The maximum plasma concentration (Cmax) of SP2086 acid
Tidsramme: up to 96 hours
|
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
|
up to 96 hours
|
|
The area under the plasma concentration-time curve (AUC) of SP2086
Tidsramme: up to 96 hours
|
AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of a single dose of SP2086
|
up to 96 hours
|
|
The area under the plasma concentration-time curve (AUC) of SP2086 acid
Tidsramme: up to 96 hours
|
AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of a single dose of SP2086
|
up to 96 hours
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antallet af frivillige med uønskede hændelser som et mål for sikkerhed og tolerabilitet
Tidsramme: op til 96 timer
|
op til 96 timer
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Jia Miao, P.H.D, West China Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juni 2014
Primær færdiggørelse (Faktiske)
1. januar 2015
Studieafslutning (Faktiske)
1. januar 2015
Datoer for studieregistrering
Først indsendt
3. januar 2016
Først indsendt, der opfyldte QC-kriterier
23. juni 2016
Først opslået (Skøn)
28. juni 2016
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
28. juni 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. juni 2016
Sidst verificeret
1. juni 2016
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HR-SP2086-Ih
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Nyreinsufficiens
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutteringSphingosin Phosphate Lyase Insufficiency Syndrome (SPLIS)Forenede Stater
-
Uppsala UniversityUppsala University HospitalIkke rekrutterer endnuMR | Anæstesi | Renal blodgennemstrømning | Renal iltning
-
Universitaire Ziekenhuizen KU LeuvenAfsluttetForekomst af Augmented Renal Clearance | Risikofaktorer for øget renal clearanceBelgien
-
The First People's Hospital of ChangzhouIkke rekrutterer endnu
-
Medical University of ViennaAfsluttetGlomerulær filtreringshastighed | Fedtsyrer, ikke-esterificerede | Renal Cirkulation | Renal Plasma FlowØstrig
-
Andrew B AdamsBristol-Myers SquibbAfsluttet
-
Hospices Civils de LyonAfsluttetSkadelig virkning | Renal toksicitetFrankrig
-
University Health Network, TorontoAfsluttetGlomerulær filtreringshastighed | Renal blodgennemstrømningCanada
-
National Cancer Institute (NCI)AfsluttetLunge | Bryst | Ovarie | Cervikal | RenalForenede Stater
Kliniske forsøg med SP2086
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Jiangsu HengRui Medicine Co., Ltd.Afsluttet
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt
-
Jiangsu HengRui Medicine Co., Ltd.Afsluttet
-
Jiangsu HengRui Medicine Co., Ltd.AfsluttetType 2 diabetes
-
Jiangsu HengRui Medicine Co., Ltd.Afsluttet
-
Jiangsu HengRui Medicine Co., Ltd.Ukendt